
CorMedix (CRMD) Stock Forecast & Price Target
CorMedix (CRMD) Analyst Ratings
Bulls say
Cormedix Inc. is positioned favorably for growth due to the expansion of its product DefenCath into total parenteral nutrition (TPN), which increases the eligible patient base and enhances revenue potential beyond 2027. The company's forecast indicates a substantial improvement in DefenCath pricing by 3x-5x based on the TDAPA formula and anticipates sales reaching between $100 million and $140 million by 2027, driven by changes in dialysis reimbursement practices. Additionally, the recent acquisition of Momenta is expected to contribute approximately $140 million in pro forma revenue, while achieving operational synergies exceeding $35 million shortly after, reinforcing Cormedix's stability and growth trajectory.
Bears say
Cormedix, Inc. issued disappointing revenue guidance for 2026 and 2027, with projected top-line sales of $300MM-$320MM falling significantly short of market consensus expectations of $423MM. The anticipated sales for its primary product, DefenCath, are expected to decline to $150MM-$170MM, which indicates a substantial decrease from prior year estimates and raises concerns about the product's competitive viability against generics and its potential for market capture. Additionally, market research highlights high discontinuation rates due to toxicity and interactions associated with its treatment regimens, creating further headwinds for the company's financial prospects.
This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.
CorMedix (CRMD) Analyst Forecast & Price Prediction
Start investing in CorMedix (CRMD)
Order type
Buy in
Order amount
Est. shares
0 shares